Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Tuesday 05 May, 2020

JP Morgan Sec LLC

Allergan plc 38.5(b)

RNS Number : 9818L
J.P. Morgan Securities LLC
05 May 2020
 

Ap27

 

 

FORM   38.5(b)

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT RECOGNISED INTERMEDIARY STATUS, 

OR WITH RECOGNISED INTERMEDIARY STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

 

 

1.  KEY   INFORMATION

 

Nameofexemptprincipaltrader

J.P Morgan Securities LLC

Companydealtin

Allergan plc

Classofrelevantsecuritytowhichthe dealingsbeingdisclosedrelate (Note 1)

Ordinary Share

Date of dealing

4 May 2020

 

2.  INTERESTS AND SHORT POSITIONS

 

(a)  Interests   and   short   positions   (following   dealing)   in   the   class   of   relevant   security   dealt   in   (Note   2)

 

 

Short

 

Number

 

(%)

Number

 

(%)

(1)Relevantsecurities

 4,979,917  1.51

 3,469,504  1.05

(2) Derivatives (other than options)

 3,818,049  1.16

 4,241,576  1.29

(3)Optionsandagreementstopurchase/sell

 305,000  0.09

 0  0.00

Total

 9,102,966  2.76

 7,711,080  2.34

             

 

 

(b)  Interests and short positions in relevant securities of the company, other than the class dealt in  (Note   2)

 

Classofrelevantsecurity:

Short

 

Number

 

(%)

Number

 

(%)

(1)Relevantsecurities

 

 

(2) Derivatives (other than options)

 

 

(3)Optionsandagreementstopurchase/sell

 

 

Total

 

 

             

 

Ap28

 

 

3.  DEALINGS  (Note   3)

 

(a)  Purchases and sales

 

Purchase/sale

Numberofrelevantsecurities

Priceperunit (Note 4)

Purchases

 

 

 

 

 

 

 

 

 

 

Sales

28

51

13

15

25

50,273

81

85

100

3

 

11,908

873

100

1

3,001

88

50

5,772

100

101

3

643

8,433

6

6,950

3

58

260

469

20

3,351

100

575

4,694

697

3

1

1,631

46

18

300

200

1

200

11

100

15

21

3

188.4121 USD

188.4863 USD

188.5400 USD

188.5500 USD

188.6192 USD

188.7000 USD

188.8950 USD

188.9200 USD

189.0800 USD

189.7400 USD

 

188.0961 USD

188.1160 USD

188.1300 USD

188.1500 USD

188.1987 USD

188.2000 USD

188.2200 USD

188.2213 USD

188.2250 USD

188.2636 USD

188.2900 USD

188.3112 USD

188.3279 USD

188.3350 USD

188.3400 USD

188.3500 USD

188.3598 USD

188.4050 USD

188.4100 USD

188.5135 USD

188.5652 USD

188.5940 USD

188.6000 USD

188.6459 USD

188.6550 USD

188.6567 USD

188.6600 USD

188.6950 USD

188.7000 USD

188.7300 USD

188.7767 USD

188.7850 USD

188.8300 USD

188.8400 USD

188.9400 USD

188.9600 USD

189.0067 USD

189.0100 USD

189.7400 USD

 

 

(b)  Derivatives transactions (other than options transactions)

 

Productname,

e.g. CFD

Natureoftransaction

(Note 5)

Numberofrelevantsecurities

(Note 6)

Priceperunit

(USD)

(Note 4)

Equity Swap

Long

46

188.7000

 

 

(c)  Options transactions in respect of existing relevant securities

 

 

(i)  Writing,   selling, purchasing or varying

 

Productname,

e.g. call option

Writing, selling,purchasing,varyingetc.

Numberofsecurities towhichtheoptionrelates (Note 7)

Exercise price

Type, e.g.American,Europeanetc.

Expiry date

Optionmoney paid/receivedperunit (Note 4)

 

 

 

 

 

 

 

 

 

(ii)  Exercising

 

Productname,

e.g. call option

Numberofsecurities

Exercisepriceper unit (Note 4)

 

 

 

 

 

(d)  Other   dealings   (including   transactions   in   respect   of   new   securities)   (Note   3)

 

Nature of transaction

(Note 7)

Details

Price per unit

(if applicable) (Note 4)

 

 

 

 

Ap29

 

4.  OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

Full details of any agreement, arrangement or understanding between the person disclosing and 

any   other   person   relating   to   the   voting   rights   of   any   relevant   securities   under   any   option   referred   to  

on   this   form   or   relating   to   the   voting   rights  or future acquisition or disposal of any relevant securities 

to which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

 

 

 

 

 

Is a Supplemental Form 38.5(b) attached?  (Note   8)    YES

 

 

Dateofdisclosure

5 May 2020

Contactname

Alwyn Basch

Telephone number

020 7742 7407

Name of offeree/offeror with which connected

Allergan plc

Nature of connection (Note 9)

Financial Advisor to Allergan plc

 

 

 

Ap31

 

 

SUPPLEMENTAL   FORM   38.5(b)

 

 

 

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DETAILS   OF OPEN POSITIONS

 

(This   form   should   be   attached   to   Form   38.5(b))   OPEN POSITIONS  (Note   1)

 

Productname,

e.g. call option

Written orpurchased

Numberofrelevant securitiestowhichtheoptionorderivativerelates

Exercise price (Note 2)

Type, e.g.American,Europeanetc.

Expiry date

Put Option

Put Option

Written

Written

300,000

5,000

150.00

140.00

American

American

19JUN20

19JUN20

 

 

 

 

Notes

 

1.  Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.

 

2.  For all prices and other monetary amounts, the currency must be stated.

 

For full details of disclosure requirements, see Rules 8 and

38.5 of the Rules. If in doubt, consult the Panel.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISEDZGGKGKDGGZM

a d v e r t i s e m e n t